CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 185 filers reported holding CHINOOK THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 7.73 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,305,661 | -74.7% | 60,012 | -84.8% | 0.01% | -94.2% |
| Q1 2023 | $9,123,415 | +165.1% | 394,100 | +200.0% | 0.14% | +117.5% |
| Q4 2022 | $3,442,025 | -41.1% | 131,375 | -55.8% | 0.06% | -43.8% |
| Q3 2022 | $5,847,000 | +20.9% | 297,384 | +7.5% | 0.11% | -15.8% |
| Q2 2022 | $4,837,000 | +70.4% | 276,538 | +59.4% | 0.13% | +75.0% |
| Q1 2022 | $2,839,000 | -1.4% | 173,503 | -1.7% | 0.08% | -14.6% |
| Q4 2021 | $2,880,000 | +1130.8% | 176,551 | +965.7% | 0.09% | +1012.5% |
| Q2 2021 | $234,000 | – | 16,567 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $198,319,737 | 34.81% |
| Saturn V Capital Management LP | 524,811 | $20,163,239 | 11.18% |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $166,956,377 | 9.97% |
| Altium Capital Management LP | 305,000 | $11,718,100 | 8.87% |
| MPM BioImpact LLC | 1,003,406 | $38,550,859 | 7.76% |
| Affinity Asset Advisors, LLC | 321,017 | $12,333,473 | 4.31% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,131,000 | $81,873,020 | 3.69% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,748,141 | $67,163,577 | 3.59% |
| Nan Fung Group Holdings Ltd | 113,950 | $4,377,959 | 2.80% |
| Vivo Capital, LLC | 934,879 | $35,918,051 | 2.48% |